{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.4","upperLimit":"6.7","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"The PFS was defined as the time from the start of treatment to progressive disease (PD) determined by PI or until death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 of a 28 day cycle","id":"OG000","title":"Carfilzomib (A0)"}],"paramType":"MEDIAN","populationDescription":"Response-evaluable Population: Enrolled patients who completed at least 1 cycle of carfilzomib and who underwent disease assessments at Screening, Cycle 1 Day 15, and Cycle 2 Day 24. This analysis set also included patients who discontinued treatment during this time due to an AE that was considered probably related to carfilzomib.","reportingStatus":"POSTED","timeFrame":"Response assessments same as described in primary outcome measure","title":"Progression-free Survival (A0 Only)","type":"SECONDARY","unitOfMeasure":"months"}